当前位置:对照品 > 实验试剂 > 生化试剂 >
达比加群酯,≥99%
  【编号】:129995

  【产品名称】:达比加群酯,≥99%

  【规格】:5MG

  【用途】:

  达比加群酯,≥99%

  Product Name: Dabigatran Etexilate
  别名:(E)-ethyl 3-(2-((4-(N'-(hexyloxycarbonyl)carbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate
  CAS号:211915-06-9
  分子式:C34H41N7O5
  分子量:627.73
  贮存: 储存温度-20°C
  可溶性:
  DMSO 126 mg/mL
  Water <1 mg/mL
  Ethanol 12 mg/mL
  生化和生理学机理:
  Description:
  IC50 Value: 4.5nM (Ki); 10nM(Thrombin-induced platelet aggregation) [1]
  Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) undergoing advanced clinical development as its orally active prodrug,dabigatran etexilate.
  in vitro: Dabigatran selectively and reversibly inhibited human thrombin(Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC(50): 10 nM), while showing no inhibitory effect on other platelet-stimulating agents.Thrombin generation in platelet-poor plasma (PPP), measured as the endogenous thrombin potential (ETP) was inhibited concentration-dependently (IC(50): 0.56 microM). Dabigatran demonstrated concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 microM, respectively [1].
  in vivo: Dabigatran prolonged the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively [1]. Patients treated with dabigatran etexilate experienced fewer ischaemic strokes (3.74 dabigatran etexilate vs 3.97 warfarin) and fewer combined intracranial haemorrhages and haemorrhagic strokes (0.43 dabigatran etexilate vs 0.99 warfarin) per 100 patient-years [2].www.atcc360.com
  Clinical trial: An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients . Phase1
上一篇:多尼培南水合物,≥99% 下一篇:地奈德,≥99%



    
    首 页 | 对照品| 标准品| 标准物质| 实验试剂| 培养基| 菌种购买| 新闻中心| 联系我们| 网站地图

    2011-2018 北京莱耀生物版权所有豫ICP备17046142号